TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction

TScan Therapeutics announced a corporate reorganization focused on its in vivo solid tumor pipeline, alongside a workforce reduction of ~75%. The move signals near-term operational cost pressure and a refocus of priorities, which may be viewed negatively on execution and funding risk even if strategically aimed at improving pipeline concentration.